Oryzon Genomics S.A. (BME:ORY)

Oryzon Genomics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14.68	28.35	5.62	12.26	21.32	28.72
Cash & Short-Term Investments	14.68	28.35	5.62	12.26	21.32	28.72
Cash Growth	-52.81%	404.61%	-54.16%	-42.50%	-25.79%	-27.47%
Accounts Receivable	2.15	2.2	3.02	1.91	3.71	3.64
Other Receivables	0.03	-	-	-	-	-
Total Trade Receivables	2.19	2.2	3.02	1.91	3.71	3.64
Inventory	0.01	0	0	0.01	0.01	0.1
Other Current Assets	0.21	0.11	0.11	0.1	0.13	0.13
Total Current Assets	17.09	30.67	8.75	14.28	25.16	32.61
Net Property, Plant & Equipment	0.47	0.38	0.36	0.48	0.61	0.68
Other Intangible Assets	117.81	109.22	98.23	89.9	75.84	60.25
Long-Term Investments	0.13	0.13	0.13	0.03	0.03	0.03
Other Long-Term Assets	5.16	4.13	2.39	2.22	2.05	1.81
Total Assets	140.61	144.52	109.85	106.9	103.7	95.38

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.64	7.32	5.76	8.42	11.48	7.04
Short-Term Debt	11.71	21.98	17.62	24.37	25.82	8.61
Current Portion of Leases	0.02	0.02	-	0.02	0.02	-
Other Current Liabilities	0	1.1	0.05	0.01	0.14	0.85
Total Current Liabilities	21.37	15.77	11.74	16.41	18.73	8.67
Long-Term Debt	4.93	6.75	7.45	6.28	10.27	13.35
Long-Term Leases	-	0.01	-	0.06	0.08	-
Other Long-Term Liabilities	5.43	4.17	2.48	2.53	2.05	2.38
Total Long-Term Liabilities	10.36	10.91	9.94	8.71	12.4	15.45
Total Liabilities	31.74	26.68	21.67	25.13	31.13	24.12

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	3.99	3.99	3.29	3.06	2.78	2.65
Treasury Stock	-5.8	-5.81	-2.03	-0.55	-0.62	-0.69
Additional Paid-in Capital	132.16	132.16	100.72	92.38	79.69	73.96
Accumulated Other Comprehensive Income	-	-	-	-1.8	-1	-
Retained Earnings	-26.13	-24.9	-20.97	-17.98	-14.42	-10.09
Total Common Shareholders' Equity	104.23	105.45	81	75.11	66.42	65.83
Minority Interest	15.48	12.4	7.17	6.67	6.15	5.44
Shareholders' Equity	119.7	117.85	88.17	81.77	72.57	71.26
Total Liabilities & Equity	140.61	144.52	109.85	106.9	103.7	95.38

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	16.67	28.76	25.07	30.72	36.19	21.97
Net Cash (Debt)	-1.98	-0.41	-19.45	-18.47	-14.87	6.76
Net Cash Growth	-	-	-	-	-	-68.14%
Net Cash Per Share	-0.03	-0.01	-0.31	-0.24	-0.27	0.13
Book Value	104.23	105.45	81	75.11	66.42	65.83
Book Value Per Share	1.35	1.42	1.29	0.97	1.21	1.25
Tangible Book Value	-13.58	-3.77	-17.22	-14.79	-9.42	5.57
Tangible Book Value Per Share	-0.18	-0.05	-0.27	-0.19	-0.17	0.11

Data Source: Fiscal.ai Last updated: Jul 27, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 4, 2026

Data Sources Report a data error